A Phase IV Study to Assess the Efficacy and Safety of Dapagliflozin Compared With Acarbose in Drug-Naive Patients With T2DM in China
Condition: Type 2 Diabetes Mellitus Intervention: Drug: Dapagliflozin/Acarbose Sponsor: AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acarbose | AstraZeneca | China Health | Dapagliflozin | Endocrinology | Forxiga | Research | Study